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Background: Several studies have shown potential benefits of antioxidants in the treatment of 
Parkinson’s disease (PD) but none have combined vitamins C and E targeting the oxidative 
stress (OS). Aim: To evaluate the neuroprotective effect of co-administration of vitamins C + 
E or single vitamin, on parameters of reserpine-induced OS in mice.  Methods: Twenty-five 
mice were randomly assigned into 5 groups.:  Group I received only distilled water (control); 
other groups received reserpine 0.1 mg/kg intraperitoneally on alternate days. In addition, 
Group III received vitamin E 200 mg/kg/day orally; group IV, had vitamin C 250 mg/kg/day 
orally and group V, had both vitamins orally. All drugs were given concurrently for 28 days. 
The mice were humanely acrificed and brain homogenate made to assess for biomarkers of 
OS. Data were expressed as mean ± SEM and values at p < 0.05 were considered significant. 
Results: The significant increase in malondialdehyde concentrations observed in the Res group 
(42.2±0.28 Umol/L) compared to control (37.54±1.27 Umol/L), was ameliorated in all the 
vitamin-treated groups with significance in the Res+Vit C group (35.0±1.69 Umol/L) 
compared to the Res group (p=0.002). Superoxide dismutase (SOD) activity increased 
significantly (p=0.003) across the vitamin-treated groups (24.9±2.11 Umol/mg, 24.0±1.78 
Umol/mg and 22.4±1.50 Umol/mg in the Res+Vit E, Res+Vit C and co-administered groups 
respectively) compared to control (14.3±1.65 Umol/mg), with non-significant increase in the 
Res group (20.6±1.42 Umol/mg); catalase activity increased significantly in the Res+Vit C 
(28.0±3.70 Umol/mg) and co-administered (30.2±2.22 Umol/mg) groups compared to controls 
(14.3±1.65 Umol/mg) and Res (20.6±1.42 Umol/mg) groups (p=0.000), with non-significant 
increase in the Res+Vit E group (17.6±0.68 Umol/mg). The highest GSH level was seen in the 
Res group (45.2±2.65 Umol/mgpr) and the lowest level seen in the Res+Vit E group (38.58 ± 
1.78 Umol/mgpr) with no significant difference across all the groups (p=0.104). Conclusion: 
The co-administration of vitamins C and E fails to confer significant superior neuroprotection 
against reserpine-induced OS compared to single vitamin administration. 
 
© Copyright 2019 African Association of Physiological Sciences -ISSN: 2315-9987. All rights reserved
 
INTRODUCTION   
Parkinson’s disease (PD), first described by James 
Parkinson (1817), is the most common movement 
disorder affecting about 1.5% of the world’s population 
over 65 years of age (~10million) (Blesa and 
Przedborski, 2014). This prevalence increases with 
advancing age to about 5% in those above 85 years 
(Farn, 2003) and the prevalence is projected to double 
by 2040 due to increasing life expectancy with higher
 
aging population and increasing industrialization 
(Dorsey et al., 2018). It is the second most common 
neurodegenerative disease (NDD) (Tanner and Aston, 
2000; Lee et al. 2009). Neurological disorders are now 
noted to be the leading cause of disability worldwide, 
among which, PD is the fastest growing (Dorsey and 
Bloem, 2018). 
Several conventional (Schapira, 2005; Clark, 2007; 
Davie, 2008; Weinreb et al., 2010; Thomas, 2017) and 
other treatment strategies such as nicotine (Barreto et 
al., 2015), non-steroidal anti-inflammatory drugs, 
NSAIDs (Wahner et al., 2007; Gagne et al., 2010), 





Vitamins and oxidative stress in mice 
 
     J. Afr. Ass. Physiol. Sci. 7 (1): 2019         Danboyi et al. 
 
 
(Joghataie et al., 2004; Saaksjarvi et al., 2008) etc. 
have been explored in the treatment of PD but some of 
these findings for example nicotine, are controversial 
(Ferrea and Winterer, 2009). Even the gold standard in 
PD treatment, l-dopa and carbidopa (a peripherial 
decarboxylase inhibitor), is associated with dyskinesia 
and end-of-dose “wearing-off” (Fahn, 1999) and it has 
been suggested that l-dopa might be neurotoxic, 
hastening the progression of PD via oxidative stress 
(Cracium et al., 2016). Although the motor symptoms 
initially respond well to pharmacologic therapies, none 
has been shown to slow down or halt the disease 
progression (Elmer and Hauser, 2013). Hence, the need 
to explore newer neuroprotective agents that can target 
the main pathophysiology of the disease with the aim of 
preventing further damage or neuronal loss, halting the 
progression, ameliorating symptoms and initiating 
repair or healing processes. 
Given the well-established central role of oxidative 
stress (OS) in the pathogenesis of PD (Jenner, 2003), 
the focus in PD therapy is now shifting to antioxidants 
such as vitamins E and C, which might protect against 
oxidative damage by neutralising free radicals. Both 
vitamins C and E had been shown to have 
neuroprotective effects as individual antioxidants in 
some studies (Roghani and Behzadi, 2001; Miyake et 
al., 2011; Harrison, 2012) but the co-administration of 
both vitamins was shown to be of greater efficacy 
against oxidative stress and nephrotoxicity in rodents 
(Khadkhodaee et al., 2008), with more potent 
antidiabetic effects (Tanko et al., 2014), although, in 
another study, this was shown to be otherwise 
(Mohammed et al., 2015). The combined 
administration of the two vitamins has been shown to 
potentiate the effect of each other on reserpine-induced 
oral dyskinesia in rodents (Faria et al., 2005), also 
suggesting that the combination of both vitamins 
provide a complete antioxidant defence (Mahadik et al., 
2001). 
 
Vitamin C plays an important role in recycling of 
vitamin E (Kohen and Nyska, 2002; Harrison, 2012), a 
process that results in the formation of vitamin C (semi-
ascorbyl) radical (Powers and Jackson, 2008; Pillai and 
Yao, 2015). Therefore, a combination of the two 
vitamins, due to their synergistic interaction (Baptista-
Ortega and Ruiz-Feria, 2010; Yarube and Ayo, 2011; 
Dawud et al, 2014; Bursac-Metrovic et al., 2016), may 
enhance their antioxidant benefit. The aim of this study 
is to evaluate the effects of co-administration of 
vitamin C (l-ascorbic acid) and vitamin E (α-
tocopherol) on reserpine-induced oxidative stress and 
parkinsonism in mice. 
METHODS 
Vitamins C and E and reserpine were of analytical 
grade and purchased from MedChem Express, U.S.A. 
The reserpine was dissolved in 0.5% glacial acetic acid, 
vitamin E (alpha-tocopherol acetate) in dimethyl 




Ethical clearance/approval was sought from the 
Ahmadu Bello University Ethical Committee on 
Research Animals Use and Care. The study was 
conducted in accordance with the guidelines of the 
A.B.U Animals Use and Care Policy. 
 
Experimental Animals 
A total of 25 mice, 8-12 weeks old and weighing 20-
30g were housed in plastic cages under standard 
environmental conditions with free access to 
commercial grower mash feed and water. 
 
Induction of Parkinsonism 
Parkinsonism was induced by alternate day’s 
administration of 0.1mg/kg reserpine injection i.p over 
4weeks (Sarmento-Silva et al., 2014).  
 
Animal Grouping 
The mice were randomly assigned into five (5) groups 
of 5 animals each:  
Group I (n=5): were fed with normal diet ad libitum 
plus normal saline (1ml/kg) throughout the study 
period. This group served as normal control. 
Group II (n=5): received reserpine (0.1mg/kg) i.p on 
alternate days (Sarmento-Silva et al., 2014) for 4 
weeks. They served as positive control. 
Group III (n=5): were pre-treated with vitamin C 
(250mg/kg) i.p daily plus reserpine (0.1mg/kg) i.p on 
alternate days for 4 weeks. 
Group IV (n=5): were pre-treated with vitamin E 
(200mg/kg) i.p daily plus reserpine (0.1mg/kg) i.p on 
alternate days for 4 weeks. 
Group V (n=5): were pre-treated with vitamin C 
(250mg/kg) i.p and vitamin E (200mg/kg) i.p daily plus 
reserpine (0.1mg/kg) i.p on alternate days for 4weeks.  
 
Homogenate Preparation 
The mice were humanely sacrificed by anaesthetizing 
them with i.p ketamine (10 mg/kg) and i.p diazepam (2 
mg/kg). As soon as the effect of anaesthesia is evident, 
the brain was carefully harvested and a homogenate 
was prepared as described by Freitas et al. (2005), 
using phosphate buffer solution. The homogenate was 
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used for analysis of biomarkers for OS (according to 
the manufacturer’s manual/guidelines).  
 
Assay for Biomarkers of Oxidative Stress 
Protocol for assay of superoxide dismutase (SOD) 
activity 
Activity of SOD was carried out according to the 
method described by Misra and Fridovich (1972).  The 
assay is based on the principle of superoxide dismutase 
(SOD) inhibition of auto-oxidation of adrenaline at pH 
of 10.2. 0.2 ml of diluted homogenate (0.1ml of 
homogenate plus 0.9ml of distilled water i.e. dilution 
factor of 1:10) was mixed with 2.5 ml of 0.05 mM 
carbonate buffer (14.3 g of Na2CO3 and 4.2 g NAHCO3 
plus 1,000 ml distilled water at pH of 10.2) and 0.3 ml 
of 0.3mM adrenaline (0.01 g of adrenaline plus 17 ml 
of distilled water). The absorbance was measured over 




Hence, the concentration of the SOD activity (in 
Umol/mg) is the amount of SOD required to elicit 50% 
inhibition of adrenaline auto-oxidation per minute. 
 
Protocol for assay of reduced glutathione (GSH) 
activity 
Reduced glutathione (GSH) activity was carried out 
according to the method described by Ellman (1959) as 
modified by Rajagopalan et al. (2004). It is based on 
the reaction of 5,5’-dithiobis nitro benzoic acid 
(DNTB) with GSH. To 150 uL of the homogenate 1.5 
ml of 10% trichloroacetic acid (10g of TCA dissolved 
in distilled water up to 100 ml in a volumetric flask) 
was added and centrifuged at 1500 g for 5 minutes. 1ml 
of the supernatant was mixed with 0.5 ml of Ellman’s 
reagent (19.8g of DNTB in 100ml of 0.1% sodium). 
 
Protocol for assay of catalase (CAT) activity 
Catalase activity was measured according to the 
method described by Aebi (1984). The principle is 
based on the decrease in absorbance of the sample 
induced by the catalytic decomposition of H2O2 to H2O 
and O2 in the presence of catalase. This enzymatic 
decomposition of H2O2 is a first order reaction, the rate 
of which is directly proportional to the amount of H2O2 
present in the homogenate. 2.8 ml of the homogenate 
was added to 0.1 ml of 30mM H2O2 in a test tube and 
the rate of decomposition was measured at 240 nm for 
5minutes using the spectrophotometer. Catalase activity 
was calculated using the molar extinction coefficient 
(E) of 0.041mM-1cm-1 as: 
Catalase concentration = absorbance / E  
Protocol for determination of MDA concentrations 
The level of thiobarbituric-acid (TBA) reactive 
substance (TBARS), as an index  of lipid 
peroxidation was determined by quantitative 
measurement of MDA concentration based on the 
method described by Okhawa et al. (1979), as modified 
by Atawodi et al. (2011). The principle is based on the 
reaction of 14% trichloroacetic acid (TCA) and 0.67% 
TBA solution both of which were added to about 100 
μL of the supernatant, forming a TBARS, an adduct 
that absorbs strongly at 532 nm. The supernatant was 
deproteinized by addition of the TCA and the mixture 
was heated in a water bath at 80oC for 30minutes 
before cooling on ice then centrifuged at 2000 g for 10 
minutes. The product of lipid peroxidation, MDA is 
expected to be released by the deproteinization and 
react with the TBA forming the coloured product, 
MDA-TBA (or TBARS), absorbance of which was 
measured at 532 nm with a UV spectrophotometer. The 
concentrations of TBARS were calculated as the 
absorbance/molar extinction coefficient of 
malondialdehyde: 1.56×105 mol/L/cm. All TBARS 
concentrations are expressed in μmol/g tissue protein. 
 
Statistical Analysis 
Data were expressed as mean ± SEM and analysed 
using one-way analysis of variance (ANOVA), 
followed Tukey’s post-hoc test. Values at p<0.05 were 




Fig. 1. MDA concentration by group: Res= Reserpine, Vit= 
vitamin. ap < 0.05 indicates statistically significant difference 
compared to control, bp < 0.05 compared to Res group, cp < 
0.05 compared to Res + Vit E, and dp < 0.05 compared to 
Res + Vit C group (One-way ANOVA followed by Tukey’s 
post-hoc test).  
32
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Level of SOD activity 
There was a significant increase in the level of SOD 
activity across the vitamin-treated groups (24.0±1.78 
Umol/mg by vitamin C, 24.9±2.11 Umol/mg by 
vitamin E and 22.4±1.5 Umol/mg by both vitamins). F 
= 5.660, p = 0.003.  
 
Fig. 2. Level of SOD activity by group: Res= Reserpine, 
Vit= vitamin. ap < 0.05 indicates statistically significant 
difference compared to the control (One-way ANOVA 
followed by Tukey’s post-hoc test).  
 
Level of CAT activity 
There was significant increase in catalase activity in the 
Res+Vit C (28.0±3.70 Umol/mg) and co-administered 
(30.2±2.22 Umol/mg) groups compared to both control 
(14.3±1.65 Umol/mg) and Res (20.6±1.42 Umol/mg) 
groups, with non-significant increase in the Res+Vit E 
group (17.6±0.68 Umol/mg). F = 2.214, p = 0.000. 
 
Fig. 3. Level of CAT activity by group: Res = Reserpine, 
Vit = vitamin. Superscripts ap < 0.05 indicates statistically 
significant difference compared to control and bp < 0.05 
compared to Res group (One-way ANOVA followed by 
Tukey’s post-hoc test).  
GSH level 
There was no significant difference in the GSH level 
across the groups, the highest level seen in the Res 
group (45.18 ± 2.65 Umol/mgpr) and the lowest level 
seen in the Res + Vit E group (38.58 ± 1.78 
Umol/mgpr). F = 2.214, p = 0.104. 
 
Table 1: Reduced glutathione levels by groups 
 
Groups Reduced Glutathione 
(GSH) (Umol/mgpr) 
Control 39.72±1.45 
Res only (0.1 mg/kg) 45.18±2.65 
Res + Vit E (200 mg/kg) 38.58±1.78 
Res + Vit C (250 mg/kg) 43.08±1.67 
Res + Vit C + Vit E 41.82±0.74 
Res= Reserpine, Vit= vitamin. No statistically significant 





Oxidative stress (OS) can be defined as an imbalance 
between the levels of ROS produced and the ability of 
the biological system to neutralize them, creating a 
state of possible cellular damage (Dias et al., 2013). It 
can also be defined as the presence of ROS in excess of 
the available antioxidant buffering capacity (Czerska et 
al., 2015). These ROS may damage DNA, proteins, 
lipids, proteins and carbohydrates changing 
the organism’s structure and functions (Czerska et al., 
2015). There is normally a balance between production 
of ROS and the antioxidant defence against them and 
any disturbance of such balance is capable of causing 
OS. Within the cell where oxygen metabolism takes 
place, ROS are normally and constantly formed as part 
of normal physiological processes with the majority of 
endogenous ROS generated by the mETC during the 
production of ATP (Eckert et al., 2003). The 
antioxidant defence consist of enzymatic and non-
enzymatic antioxidants.  
The mechanism involved in toxin-induced PD in well-
established animal models such as MPTP, 6-OHDA, 
rotenone and paraquat is associated with OS (Dias et 
al., 2013). Although, apart from PD, OS had also been 
linked to other NDD such as Alzheimer’s disease (AD), 
Huntington’s disease (HD) and amyotrophic lateral 
sclerosis (ALS) despite having distinct pathological and 
clinical features (Lin and Beal, 2006), supporting the 
role of oxidative stress in neurodegeneration 
(Anderson, 2004). 
Markers of lipid peroxidation such as HNE and MDA 
are increased in the SN of PD patients, while PUFAs 
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are decreased (Montine et al., 2004). Our result showed 
a significant evidence of lipid peroxidation (figure 1), 
characterized by a significant increase in MDA 
concentration in the reserpine only treated group 
compared to control. This was however, significantly 
ameliorated by vitamins C and E as single 
administrations. This is in line with the findings of 
Nayak et al., (2018), which showed neuroprotective 
effect of vitamin E against lipid peroxidation at 
different regions of rat brain. Surprisingly, vitamin C 
conferred the greater significant protection against lipid 
peroxidation, not being a membrane lipid-soluble 
antioxidant itself. This finding on the co-administered 
group is unexpected, as vitamin C to regenerate vitamin 
E in a synergistic action to produce even much greater 
significant protection against lipid peroxidation. This 
might be due to pro-oxidant activity of vitamin C at 
certain dosages, depending on the presence of transition 
metal ions such as Fe3+ (Paolini et al., 1999; Halliway 
et al., 1999). 
The increase in SOD activity seen in the reserpine-only 
treated group, could be a compensatory response to the 
OS resulting from the excessive production of free 
oxygen radicals. This is a first line of antioxidant 
defence against OS, scavenging O22- in both cytosol 
and mitochondrial inter-membrane space (Rodriguez et 
al., 2011). However, the activity of SOD in the vitamin 
groups was even significantly higher, probably due to 
augmentation of the endogenous antioxidant enzyme by 
the vitamins. Again, the co-administration did not show 
more efficacy probably due to the pro-oxidant effect of 
vitamin C. This finding is consistent with the work of 
Serra et al. (2001), but contrary to other more recent 
studies (Sunday et al., 2014; Cracium et al., 2016).  
The significant increase in CAT activity across vitamin 
groups, with the greatest significance observed in the 
group given both vitamins is probably due to their 
synergistic effect against OS (Faria et al., 2005; 
Khadkhodaee et al., 2008; Baptista-Ortega and Ruiz-
Feria, 2010; Yarube and Ayo, 2011; Dawud et al, 2014; 
Bursac-Metrovic et al., 2016). CAT is part of the 
second line antioxidant defence, scavenging for H2O2 
generated by SOD activity intracellularly (Pillay and 
Yao, 2015). Hence, increase in SOD activity will lead 
to increase in H2O2 generation, leading to a 
compensatory increase in CAT activity. 
The mild increase in GSH level, although not 
statistically significant, may be due to a compensatory 
response to increase generation of free radicals, which 
is contrary to the work of Sian et al. (1994), that 
showed decrease in GSH level in the SNc of PD brains. 
Although expected, there was no appreciable increase 
in the GSH level in the groups treated with vitamins. 
This may be due to an overwhelming level of OS and 
it’s in line with the findings of Nayak et al. (2018), who 
also found no significant alteration in GSH level in rat 
brain exposed to aluminium and ethanol toxicity, 
following vitamin E supplementation for 4 weeks. 
Since GPx catalyses a reaction in which GSH 
detoxifies H202 to water, the GSH level is expected to 
increase when there is decrease in the GPx activity, as 
seen in the present study. This is also in line with the 
findings of Sunday et al. (2014), who found decrease in 
GPx as a reciprocal to SOD activity, although other 
studies showed no significant alteration (Cracium et al., 
2016) in the GPX activity. 
All the above findings showed a significant evidence of 
OS induced by reserpine in agreement with several 
other studies (Sanghavi et al., 2010; Fernandez et al., 
2012; Eftimov et al., 2014; Hsiang-Chien et al., 2015; 
Dwivedi and Tomar, 2016). However, the 
administration of the antioxidants (vitamins C and E) 
was significantly protective against the OS, with the co-
administration of the two antioxidants more potent than 
single vitamin administration. These findings of the 
present study on biomarkers of OS is contrary to other 
studies who showed generalised decrease in the SOD, 
CAT, GPx activities and GSH level (Napolitano et al., 
2011; Koppula et al., 2012). 
The beneficial effect of antioxidants and antioxidant 
enzymes is seen in scavenging of free radicals 
generated during OS and neuroprotection These 
antioxidant systems prevent the generation and actions 
of ROS and provide a potential mechanism for 
ameliorating OS. Vitamin E, being a chain-breaking 
antioxidant within the lipid membrane (Kamal-Eldin 
and Appelqvist, 1996), protected against lipid 
peroxidation to a very significant extent as seen in this 
study and, it was itself regenerated by the vitamin C 
(Ambali et al, 2010; Harrison, 2012), which is a 
powerful water-soluble antioxidant within the 
cytoplasm and outside the membrane, and may help to 
boost the endogenous antioxidant levels. The vitamin E 
in turn, probably played a role in the biosynthesis of 
more endogenous vitamin C (Machlin and Gabriel, 
1980) to boost the antioxidant neuroprotective effect.  
 
CONCLUSION 
From this study, co-administration of vitamins C and E 
was only partially neuroprotective against reserpine-
induced OS in mice. Although, no significant 
neuroprotection was observed over the single vitamin 
administration, this finding depicts a great potential in 
slowing down the progression of NDDs like PD. 
Introducing such neuroprotective therapy, which are 
readily available and affordable, into the standard 
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treatment of PD will be highly beneficial. More studies 
are however needed, to explore these vitamins C and E 
at different dosages. 
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